Pharma Journalist -

Biogen announced that it has completed its acquisition of Nightstar Therapeutics, a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for…
Read More...

Bayer and Arvinas, a biopharmaceutical company creating a new class of therapies to degrade disease-causing proteins, announced an agreement to leverage Arvinas’ novel PROTAC protein…
Read More...

Celgene Corporation and Acceleron Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics License Application (BLA) for luspatercept, an…
Read More...

Vertex Pharmaceuticals Incorporated announced that the company is enhancing its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic…
Read More...

Novartis announced new early stage histology data in kidney transplantation, suggesting that with investigational compound iscalimab (CFZ533) it may be possible to prolong the…
Read More...

Goldfinch Bio, Inc., a biotechnology company focused on developing precision therapies for patients with kidney diseases, announced it has initiated dosing in a Phase 1 clinical trial…
Read More...

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, has signed an agreement with BDD Pharma, an award-winning drug delivery company specializing in modified and…
Read More...

Servier, an international independent pharmaceutical company, and Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, announce that they have signed a manufacturing…
Read More...

Advanced Accelerator Applications S.A. (AAA), a Novartis company, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted…
Read More...

PeptiDream Inc., a public Kanagawa-based biopharmaceutical company announced a strategic partnership with Seattle-based PharmaIN Corporation for the purpose of investigating the use of…
Read More...